The statements within the DURECT Corporation website, and affiliated websites, relating to DURECT's products in development, technology attributes or capabilities, product development plans, development timelines, expected product or technology benefits or potential product markets involve risks and uncertainties that could cause actual results to differ materially from those in such forward looking statements. Potential risks and uncertainties include, but are not limited to, our ability to develop and commercialize our products, our ability to complete successful clinical trials, our ability to obtain product approvals from regulatory agencies, marketplace acceptance of our products, our ability to successfully manufacture our products, our reliance on sole or limited suppliers, our need to train physicians to use our products, our ability to obtain adequate reimbursement from third-party payors and the introduction of competitive products by other companies, our ability to gain access to proprietary technology and drugs, our ability to enter into development or commercialization agreements with other life sciences companies and our ability to manage our growth and costs. Further information regarding these and other risks is included in the company's S-1 registration statement, quarterly reports on Form 10-Q and annual report on Form 10-K, as filed with the SEC. Copies of these documents are available on request from the Investor Relations Department of DURECT.
NOTE: POSIMIR®, SABER®, CLOUD®, TRANSDUR®, ORADUR®, ELADUR™, ALZET® and LACTEL® are trademarks of DURECT Corporation. Other trademarks referred to belong to their respective owners.